CN107429247B - 使用多价阳离子盐组合物制备多核苷酸的方法 - Google Patents

使用多价阳离子盐组合物制备多核苷酸的方法 Download PDF

Info

Publication number
CN107429247B
CN107429247B CN201680014382.0A CN201680014382A CN107429247B CN 107429247 B CN107429247 B CN 107429247B CN 201680014382 A CN201680014382 A CN 201680014382A CN 107429247 B CN107429247 B CN 107429247B
Authority
CN
China
Prior art keywords
polynucleotide
salt
composition
counterion
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680014382.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN107429247A (zh
Inventor
P·H·拉米亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geron Corp
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Priority to CN202110878917.1A priority Critical patent/CN113564168B/zh
Publication of CN107429247A publication Critical patent/CN107429247A/zh
Application granted granted Critical
Publication of CN107429247B publication Critical patent/CN107429247B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates
    • C12P19/28N-glycosides
    • C12P19/30Nucleotides
    • C12P19/34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/113Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/314Phosphoramidates
    • C12N2310/3145Phosphoramidates with the nitrogen in 3' or 5'-position
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3515Lipophilic moiety, e.g. cholesterol
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07Nucleotidyltransferases (2.7.7)
    • C12Y207/07049RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680014382.0A 2015-04-23 2016-04-21 使用多价阳离子盐组合物制备多核苷酸的方法 Active CN107429247B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110878917.1A CN113564168B (zh) 2015-04-23 2016-04-21 使用多价阳离子盐组合物制备多核苷酸的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562151891P 2015-04-23 2015-04-23
US62/151,891 2015-04-23
PCT/US2016/028657 WO2016172346A1 (en) 2015-04-23 2016-04-21 Methods of polynucleotide preparation using multivalent cation salt compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110878917.1A Division CN113564168B (zh) 2015-04-23 2016-04-21 使用多价阳离子盐组合物制备多核苷酸的方法

Publications (2)

Publication Number Publication Date
CN107429247A CN107429247A (zh) 2017-12-01
CN107429247B true CN107429247B (zh) 2021-08-13

Family

ID=55911083

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680014382.0A Active CN107429247B (zh) 2015-04-23 2016-04-21 使用多价阳离子盐组合物制备多核苷酸的方法
CN202110878917.1A Active CN113564168B (zh) 2015-04-23 2016-04-21 使用多价阳离子盐组合物制备多核苷酸的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110878917.1A Active CN113564168B (zh) 2015-04-23 2016-04-21 使用多价阳离子盐组合物制备多核苷酸的方法

Country Status (36)

Country Link
US (2) US10745687B2 (enExample)
EP (1) EP3286203B1 (enExample)
JP (4) JP2018513127A (enExample)
KR (1) KR102401252B1 (enExample)
CN (2) CN107429247B (enExample)
AU (2) AU2016250576C1 (enExample)
BR (1) BR112017019627B1 (enExample)
CA (1) CA2978191C (enExample)
CL (1) CL2017002314A1 (enExample)
CO (1) CO2017009217A2 (enExample)
CY (1) CY1123197T1 (enExample)
DK (1) DK3286203T3 (enExample)
EA (1) EA035885B1 (enExample)
ES (1) ES2798270T3 (enExample)
HR (1) HRP20201218T1 (enExample)
HU (1) HUE051148T2 (enExample)
IL (1) IL254222A0 (enExample)
LT (1) LT3286203T (enExample)
MA (2) MA42569B1 (enExample)
MD (1) MD3286203T2 (enExample)
ME (1) ME03811B (enExample)
MX (1) MX383293B (enExample)
MY (1) MY187804A (enExample)
PE (2) PE20221275A1 (enExample)
PH (1) PH12017501927B1 (enExample)
PT (1) PT3286203T (enExample)
RS (1) RS60645B1 (enExample)
SA (1) SA517390103B1 (enExample)
SG (2) SG11201707893RA (enExample)
SI (1) SI3286203T1 (enExample)
SM (1) SMT202000389T1 (enExample)
TN (1) TN2017000411A1 (enExample)
TW (1) TWI736532B (enExample)
UA (1) UA124521C2 (enExample)
WO (1) WO2016172346A1 (enExample)
ZA (1) ZA201706041B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42569B1 (fr) 2015-04-23 2020-08-31 Geron Corp Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent
US11384352B2 (en) 2016-12-13 2022-07-12 Modernatx, Inc. RNA affinity purification
EP4060345A1 (en) 2016-12-19 2022-09-21 Ventana Medical Systems, Inc. Peptide nucleic acid conjugates
US11866696B2 (en) * 2017-08-18 2024-01-09 Modernatx, Inc. Analytical HPLC methods
JP7441455B2 (ja) * 2017-09-22 2024-03-01 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイト 筋ジストロフィーの処置のためのチオモルホリノオリゴヌクレオチド
EP3727470B1 (en) 2017-12-18 2024-11-20 Ventana Medical Systems, Inc. Peptide nucleic acid conjugates

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1849069A (zh) * 2003-09-09 2006-10-18 杰龙公司 用于端粒酶抑制的改性寡核苷酸
CN101534920A (zh) * 2006-11-01 2009-09-16 比奥根艾迪克Ma公司 通过低pH和二价阳离子分离生物大分子的方法
CN103052405A (zh) * 2010-08-20 2013-04-17 里普利科股份有限公司 寡核苷酸螯合物

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046720A (en) 1974-01-17 1977-09-06 California Institute Of Technology Crosslinked, porous, polyacrylate beads
US4413070A (en) 1981-03-30 1983-11-01 California Institute Of Technology Polyacrolein microspheres
US4678814A (en) 1981-03-30 1987-07-07 California Institute Of Technology Polyacrolein microspheres
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
DE69130333T2 (de) 1990-08-31 1999-03-04 Regents Of The University Of Minnesota, Minneapolis, Minn. Harze für die Feststoff-Peptidsynthese
US5281701A (en) 1991-07-12 1994-01-25 Applied Biosystems, Inc. Process and compounds for RNA synthesis
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
PL316434A1 (en) 1994-03-18 1997-01-06 Lynx Therapeutics Oligonucleotidic phosphoramides n3'-p5', their compositions, synthesising and hydridising methods as well as immunological properties in respect to nuclease
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US5726297A (en) 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US5859233A (en) 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
AU733610B2 (en) 1996-12-20 2001-05-17 Geron Corporation Methods for detecting and inhibiting the RNA component of telomerase
US5998604A (en) 1997-09-15 1999-12-07 The Perkin-Elmer Corporation Polynucleotide purification method
US6114519A (en) 1997-10-15 2000-09-05 Isis Pharmaceuticals, Inc. Synthesis of sulfurized oligonucleotides
US6465628B1 (en) 1999-02-04 2002-10-15 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
AU767646B2 (en) 1999-09-10 2003-11-20 Geron Corporation Oligonucleotide N3'-P5' thiophosphoramidates: their synthesis and use
JP2002060341A (ja) 2000-08-21 2002-02-26 Terumo Corp 止血剤
WO2002077184A2 (en) 2001-03-23 2002-10-03 Geron Corporation Oligonucleotide conjugates
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
US20120329858A1 (en) 2010-08-04 2012-12-27 Geron Corporation Modified oligonucleotides for telomerase inhibition
TW200540180A (en) 2004-05-28 2005-12-16 Sankyo Co Telomerase inhibitor ena oligonucleotide
RS56361B1 (sr) 2004-07-02 2017-12-29 Geron Corp Sinteza zaštićenih 3'-amino nukleozidnih monomera
CN101321877B (zh) * 2005-10-03 2013-04-10 应用生物系统有限责任公司 用于扩增核酸的组合物、方法和试剂盒
US9106103B2 (en) 2011-09-23 2015-08-11 Eaton Corporation Unintteruptible power supply systems and methods employing on-demand energy storage
US9006630B2 (en) 2012-01-13 2015-04-14 Altasens, Inc. Quality of optically black reference pixels in CMOS iSoCs
AR091065A1 (es) 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
ES2770638T3 (es) * 2012-06-14 2020-07-02 Life Technologies Corp Nuevas composiciones, métodos y kits para la reacción en cadena de la polimerasa (PCR)
RS59363B1 (sr) 2012-12-07 2019-11-29 Geron Corp Upotreba inhibitora telomeraze imetelstata za lečenje mijelofibroze
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
MA42569B1 (fr) 2015-04-23 2020-08-31 Geron Corp Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1849069A (zh) * 2003-09-09 2006-10-18 杰龙公司 用于端粒酶抑制的改性寡核苷酸
CN101534920A (zh) * 2006-11-01 2009-09-16 比奥根艾迪克Ma公司 通过低pH和二价阳离子分离生物大分子的方法
CN103052405A (zh) * 2010-08-20 2013-04-17 里普利科股份有限公司 寡核苷酸螯合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A rapid method for the purification of deprotected oligodeoxynucleotides;M.Sawadogo等;《Nucleic Acids Research》;19910211;第19卷(第3期);第674页左栏 *

Also Published As

Publication number Publication date
TW201706284A (zh) 2017-02-16
EA201791753A1 (ru) 2018-04-30
CA2978191C (en) 2022-10-04
TWI736532B (zh) 2021-08-21
HUE051148T2 (hu) 2021-03-01
CL2017002314A1 (es) 2018-05-04
SG10201909816PA (en) 2019-11-28
JP2025061848A (ja) 2025-04-11
US20200339975A1 (en) 2020-10-29
BR112017019627A2 (pt) 2018-05-15
AU2016250576B2 (en) 2021-02-04
UA124521C2 (uk) 2021-10-05
SA517390103B1 (ar) 2021-07-14
AU2016250576A1 (en) 2017-09-21
KR102401252B1 (ko) 2022-05-24
AU2021202803A1 (en) 2021-06-03
CY1123197T1 (el) 2021-10-29
RS60645B1 (sr) 2020-09-30
CO2017009217A2 (es) 2018-02-20
PT3286203T (pt) 2020-07-08
ZA201706041B (en) 2020-11-25
BR112017019627B1 (pt) 2022-11-29
JP2021152079A (ja) 2021-09-30
CN113564168A (zh) 2021-10-29
AU2016250576C1 (en) 2021-05-06
NZ735042A (en) 2021-11-26
PH12017501927A1 (en) 2018-03-05
PE20171785A1 (es) 2017-12-27
CN107429247A (zh) 2017-12-01
SI3286203T1 (sl) 2020-10-30
WO2016172346A1 (en) 2016-10-27
IL254222A0 (en) 2017-10-31
MD3286203T2 (ro) 2020-08-31
MX383293B (es) 2025-03-13
PE20221275A1 (es) 2022-09-01
CN113564168B (zh) 2024-10-25
US11441144B2 (en) 2022-09-13
HK1251234A1 (en) 2019-01-25
PH12017501927B1 (en) 2022-09-02
KR20170138399A (ko) 2017-12-15
MY187804A (en) 2021-10-26
US10745687B2 (en) 2020-08-18
TN2017000411A1 (en) 2019-01-16
MA42157A (fr) 2018-02-28
SMT202000389T1 (it) 2020-09-10
SG11201707893RA (en) 2017-11-29
JP2018513127A (ja) 2018-05-24
EP3286203B1 (en) 2020-05-06
ES2798270T3 (es) 2020-12-10
EP3286203A1 (en) 2018-02-28
DK3286203T3 (da) 2020-06-02
HRP20201218T1 (hr) 2020-12-11
LT3286203T (lt) 2020-07-27
JP2022168017A (ja) 2022-11-04
EA035885B1 (ru) 2020-08-27
US20160312227A1 (en) 2016-10-27
MA42569B1 (fr) 2020-08-31
MX2017011642A (es) 2017-11-02
ME03811B (me) 2021-04-20
CA2978191A1 (en) 2016-10-27

Similar Documents

Publication Publication Date Title
CN107429247B (zh) 使用多价阳离子盐组合物制备多核苷酸的方法
JP2022044679A (ja) オリゴヌクレオチド組成物及びその作製方法
HK1242377A1 (en) Methods of polynucleotide preparation using multivalent cation salt compositions
HK1251234B (en) Methods of polynucleotide preparation using multivalent cation salt compositions
NZ735042B2 (en) Methods of polynucleotide preparation using multivalent cation salt compositions
OA18769A (en) Methods of polynucleotide preparation using multivalent cation salt compositions.
HK40030910A (en) Oligonucleotide compositions and methods of making the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1242377

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1242377

Country of ref document: HK